Online inquiry

IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ8945MR)

This product GTTS-WQ8945MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1RL2 gene. The antibody can be applied in Lymphoproliferative disease research.

Specifications
Product type	mRNA
Modified bases	Pseudo-UTP
5' Cap	Cap 1
Species	Corynebacterium diphtheriae; Homo sapiens
RefSeq	NM_001351446.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	8808
UniProt ID	Q9HB29

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8945MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ12972MR	IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	PEG sTNF-RI
GTTS-WQ14739MR	IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	SGN-19A
GTTS-WQ4053MR	IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	BI 655130
GTTS-WQ15989MR	IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	ZTS-00521505
GTTS-WQ13641MR	IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	R4930
GTTS-WQ5487MR	IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	CDP 6038
GTTS-WQ1877MR	IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	AGEN1884
GTTS-WQ8481MR	IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	HTI-1088

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST